On October 3, 2017, Pfizer, Inc. (“Pfizer”) filed a petition for inter partes review (“IPR”) against U.S. Patent No. 7,846,441...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
News
-
-
Amgen and Allergan recently announced that they submitted a Biologics License Application (“BLA”) for ABP 980, a proposed biosimilar to...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Sandoz, Inc. (“Sandoz”) entered into the battlefield over patents related to AbbVie’s Humira® (adalimumab). On July 20, 2017,...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On July 24, 2017, Samsung Bioepis and Merck & Co., Inc. announced the launch of Renflexis® (infliximab-abda) in the United States. ...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Merck & Co., Inc. (“Merck”) announced last week that the FDA has granted tentative approval for its insulin glargine injection...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Novartis’ First CAR-T Cell Therapy Tisagenlecleucel (CTL019) The FDA’s Oncologic Drug Advisory Committee (“ODAC”) held a public...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Boehringer Ingelheim International GMBH and Boehringer Ingelheim Pharmaceuticals, Inc. (“Boehringer Ingelheim”) have prevailed in two...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On June 30, 2017, Pfizer, Inc. (“Pfizer”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 8,591,897...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The patent venue statue, 28 U.S.C. § 1400(b), states that “ny civil action for patent infringement may be brought in the judicial...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]